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A B S T R A C T
Purpose
To determine the accuracy and usefulness of oncologists’ estimates of survival time in individual
patients with advanced cancer.
Patients and Methods
Twenty-one oncologists estimated the “median survival of a group of identical patients” for each
of 114 patients with advanced cancer. Accuracy was defined by the proportions of patients with
an observed survival time bounded by prespecified multiples of their estimated survival time. We
expected 50% to live longer (or shorter) than their oncologist’s estimate (calibration), 50% to live
from half to double their estimate (typical scenario), 5% to 10% to live  one quarter of their
estimate (worst-case scenario), and 5% to 10% to live three or more times their estimate
(best-case scenario). Estimates within 0.67 to 1.33 times observed survival were deemed precise.
Discriminative value was assessed with Harrell’s C-statistic and prognostic significance with
proportional hazards regression.
Results
Median survival time was 11 months. Oncologists’ estimates were relatively well-calibrated (61%
shorter than observed), imprecise (29% from 0.67 to 1.33 times observed), and moderately
discriminative (Harrell C-statistic 0.63; P  .001). The proportion of patients with an observed
survival half to double their oncologist’s estimate was 63%,  one quarter of their oncologist’s
estimate was 6%, and three or more times their oncologist’s estimate was 14%. Independent
predictors of observed survival were oncologist’s estimate (hazard ratio [HR] 0.92; P .004), dry
mouth (HR  5.1; P  .0001), alkaline phosphatase more than 101U/L (HR  2.8; P  .0002),
Karnofsky performance status  70 (HR  2.3; P  .007), prostate primary (HR  0.23; P  .002),
and steroid use (HR  2.4; P  .02).
Conclusion
Oncologists’ estimates of survival time were relatively well-calibrated, moderately discriminative,
independently associated with observed survival, and a reasonable basis for estimating worst-
case, typical, and best-case scenarios for survival.
J Clin Oncol 31:3565-3571. © 2013 by American Society of Clinical Oncology
INTRODUCTION
Most people with advanced cancer want informa-
tion about its effects on their life expectancy.1,2 This
information helps those affected by cancer evaluate
potential treatment options, optimize their remain-
ing time, set goals, and prepare for death. A survey of
126 outpatients with advanced cancer attending on-
cology clinics found that most wanted specific esti-
mates of their shortest survival time without
treatment (72%), their average survival time (81%),
and their longest survival time with effective treat-
ment (85%).2 In an independent survey of 500 peo-
ple with a cancer experience, approximately 90% of
respondents agreed that presenting prognostic in-
formation as ranges for three possible scenarios
(worst case, typical, and best case) was helpful and
preferable to presenting a single estimate of the me-
dian survival.3
Most oncologists find it difficult to estimate
and explain survival time in a manner that is accu-
rate and easy to understand and conveys an appro-
priate balance of hope and realism. Several tools
have been designed to help doctors estimate survival
for people with cancer who are at the end of life,
often when admitted to a hospital or hospice.4-8 Less
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guidance is available to help oncologists estimate survival time for
patients with advanced cancer who are attending outpatient clinics
and are not yet at the terminal phase of their illness.
In a previous study, we asked oncologists to estimate the survival
time of 102 newly referred patients with incurable cancer by estimat-
ing the median survival of a group of similar patients. We found that
approximately 10% of patients died within one sixth of their estimated
survival time (worst-case scenario), approximately 50% lived between
half to double their estimated survival time (typical scenario), and
approximately 10% lived for three or more times their estimated
survival time (best-case scenario).9 In systematic reviews of first-line
chemotherapy trials for advanced breast cancer, and for advanced
non–small-cell lung cancer, we found similar relationships between
each overall survival (OS) curve’s median and its percentiles corre-
sponding to worst-case (one quartermedian OS), typical (half to
double the median OS), and best-case (three or more times median
OS) scenarios for survival.10,11 We hypothesized that the ratio of one
quarter for the worst-case scenario in these trials, rather than of one
sixth, reflected patient selection, particularly the exclusion of patients
with a life expectancy of less than 3 months. We sought to establish the
wider applicability of using simple multiples to estimate scenarios for
survival in a cohort of patients with advanced cancer and prospectively
collected data about expected and observed survival time. The general
aims of this study were to determine the accuracy and usefulness of
medical oncologists’ estimated survival times in symptomatic patients
with advanced cancer.
PATIENTS AND METHODS
Study subjects were participants in a previously reported, randomized,
placebo-controlled trial of the effects of sertraline in people with advanced
cancer who felt depressed, anxious, fatigued, or lacking energy, but were not
thought to have major depression (the ZEST [Zoloft’s Effects on Symptoms
and Survival Time] trial).12 Eligibility criteria included a life expectancy greater
than 3 months and an Eastern Cooperative Oncology Group performance
status of 0 to 2. Twenty-one medical oncologists recruited 189 participants at
24 sites around Australia. The protocol was approved by human research
ethics committees at all participating institutions, and all patients gave written,
informed consent. Blood samples, demographics, and tumor and treatment
characteristics were collected at baseline. The survival status of each subject was
ascertained for a minimum of 12 months.
The data reported here come from consecutive subjects recruited after a
protocol amendment in October 2003 asking oncologists to record their esti-
mated survival time for each participant (as the median survival of a group of
identical patients) and to record the presence of seven specified symptoms
(problems with shortness of breath, eating, appetite, swallowing, dry mouth,
weight loss, and fatigue).
For comparability with other studies, we defined a point estimate of
survival time as precise if it was within 0.67 to 1.33 times the observed
survival time and expected approximately 20% to 30% of estimates to meet
this definition.9,13-16
We operationalized the broad concept of accuracy in terms of the pro-
portions of subjects with observed survival times bounded by simple multiples
of their oncologist’s estimated survival time. For each subject we calculated the
ratio of observed survival time (OST) to estimated survival time (EST). The
distribution of OST/EST ratios was estimated from a Kaplan-Meier analysis to
accommodate instances where the observed survival time was censored. We
expected oncologists’ estimates to be well-calibrated with approximately equal
proportions (50%) of estimates being longer than the observed survival time
(OST/EST 1) and shorter than the observed survival time (OST/EST 1).
Based on our previous studies, we expected approximately 5% to 10% of
patients to die within one quarter of their oncologist’s estimate (OST/EST
one quarter, worst-case scenario), 50% of patients to live from half to double
their oncologist’s estimate (OST/EST between 0.5 and 2, typical range), and
5% to 10% to live three or more times their oncologist’s estimate (OST/EST
3, best-case scenario).9-11 We used a multiple of one quarter to estimate the
worst-case scenario, rather than one sixth, because all participants recruited to
the trial were expected to live longer than 3 months, making the study popu-
lation more similar to the clinical trial populations from our systematic re-
views10,11 than to the all-comers population in our original study.9
The discriminative value of oncologists’ estimates of survival time was
assessed with Harrell’s C-statistic.17 The C-statistic is the probability that for a
randomly chosen pair of subjects, the subject predicted to have a better out-
come (longer survival) will experience a better outcome (longer survival). A
value of 1.0 indicates perfect predictions; a value of 0.5 indicates random
predictions (no better than tossing a coin).
Associations between estimated survival time in months and observed
survival time were assessed with Cox proportional hazards regression both
with and without adjustments for various baseline characteristics, including
primary site, past treatment, liver or brain metastases, performance status,
blood tests, sex, age, body weight, the presence of specific symptoms recorded
by oncologists, estimated neutrophil count (total WBC count minus lympho-
cyte count), and estimated neutrophil–lymphocyte ratio (estimated neutro-
phil count divided by lymphocyte count, [NLR]). The neutrophil count and
NLR are markers of systemic inflammation previously shown to have inde-
pendent prognostic value in a variety of cancers.18-26 Continuous variables
were dichotomized for inclusion as covariates in regression models. NLR was
dichotomized as 0 to 5 versus greater than 5.20,21,24,27 The cut point for
neutrophil count was the median value in this sample. The cut points for other
continuous variables were those used in the ZEST trial.12 Parameters that were
significant on univariable analysis at the 5% level were included in the starting
pool for multivariable analysis using stepwise backward elimination to deter-
mine the variables retained in the model. A second multivariable analysis was
used to determine the prognostic significance of estimated survival time in a
model including all covariates that were independently significant in the orig-
inal ZEST trial analysis (primary lung cancer, baseline opioid use, previous
chemotherapy, liver or brain metastases, Karnofsky performance status 70,
and alkaline phosphatase 101 U/L).12 Associations between the same base-
line variables and estimated survival time were assessed with linear regression.
RESULTS
Oncologists’ estimates of survival time were available for 114 (87%) of
the 131 patients enrolled in the ZEST trial between October 2003 and
February 2006. Baseline characteristics of these114 patients are sum-
marized in Table 1. After a median follow-up of 14 months (range, 1 to
30 months), there were 68 deaths, 10 within 3 months of recruitment.
The median observed survival time was 11 months, with an interquar-
tile range of 5 to 20 months. Observed and estimated survival times are
plotted in Figure 1.
The median estimated survival time was 9 months (interquartile
range, 6 to 12 months). Oncologists’ estimates were largely confined to
simple multiples of 3 or 4 months (98% of estimates), and simple
multiples of 6 months accounted for 74% of estimates (Fig 2).
The proportion of oncologists’ estimates meeting our arbitrary
criterion of precision (0.67 to 1.33 times observed survival time) was
29% (95% CI, 20% to 38%). Oncologists’ estimates were relatively
well-calibrated, with 61% (95% CI, 50% to 70%) of patients living
longer and 39% (95% CI, 30% to 50%) living shorter than their
estimated survival time. The relationship between each individual
subject’s EST and OST is shown in Figure 3. Few subjects are on the
45-degree line reflecting perfect agreement, and similar proportions
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are above and below the line, reflecting estimates that were imprecise
but relatively well-calibrated.
The proportions of subjects with OSTs falling within ranges
bounded by simple multiples of their estimated survival times corre-
sponded closely with our a priori hypotheses: 6% (95% CI, 3% to
13%) lived  one quarter of their EST (a priori hypothesis, 5% to
10%), 63% (95% CI, 54% to 72%) lived from half to double their EST
(a priori hypothesis, 50%), and14% (95% CI, 6% to 25%) lived three
or more times their EST (a priori hypothesis, 5% to 10%). Figure 4
shows the Kaplan-Meier distribution of OST/EST ratios.
Oncologists’ survival estimates had moderate discriminative
value that was statistically significantly better than the play of chance:
for all possible pairs of subjects, 63% with a longer estimated survival
time had a longer observed survival time (Harrell’s C-statistic, 0.63;
95% CI, 0.54 to 0.71; P .001).
The prognostic value of EST, and of other baseline characteris-
tics, is summarized in Table 2. On univariable analysis, 14 variables
were significantly associated with OST. Six of these, including EST
(hazard ratio [HR]  0.92; 95% CI, 0.87 to 0.98; P  .004), were
independently significant predictors on multivariable analysis. EST
Table 1. Baseline Characteristics
Characteristic No. %
Age, years
 50 8 7
50-59 30 26
60-69 36 32
70-79 29 25
 80 11 10
Sex
Male 61 54
Female 53 46
ECOG performance status
0 9 8
1 81 71
2 24 21
Karnofsky performance status
100 2 2
90 23 20
80 60 53
70 26 23
60 2 2
50 1 1
Primary cancer site
Breast 21 18
Lung 17 15
Colorectal 18 16
Prostate 14 12
Ovary 11 10
Pancreas/biliary 6 5
Kidney/urothelial 4 4
Other 23 20
Time since diagnosis with advanced cancer, months
Median 8.5
Range 3.6-19.4
Sites of metastases (any No. per patient)
Bone 32 28
Liver 35 31
Lung or pleura 37 32
Brain 4 4
Previous anticancer treatment (ever)
Chemotherapy 86 75
Surgery 67 59
Radiotherapy 54 47
Endocrine therapy 36 32
Recent anticancer treatment (past 30 days)
Chemotherapy 48 42
Endocrine therapy 6 5
Radiation therapy 3 3
Surgery 2 2
Supportive treatments in use at baseline
Opioids 29 25
Steroids 12 11
Laboratory measurements
Hemoglobin, g/L
Median 124
Interquartile range 115-136
WBC count,  109/L
Median 6.5
Interquartile range 4.8-8.8
Lymphocytes,  109/L
Median 1.5
Interquartile range 1.0-2.0
(continued in next column)
Table 1. Baseline Characteristics (continued)
Characteristic No. %
Albumin, g/L
Median 39
Interquartile range 35-41
Alkaline phosphatase, U/L
Median 100
Interquartile range 81-148
Creatinine, mol/L
Median 73
Interquartile range 56-95
C-reactive protein, mg/L
Median 10
Interquartile range 5-29
Bilirubin, mmol/L
Median 9
Interquartile range 7-13
Abbreviation: ECOG, Eastern Cooperative Oncology Group.
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Fig 1. Kaplan-Meier curves of observed survival and estimated survival.
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was also an independently significant predictor (HR 0.93; 95% CI,
0.88 to 0.99; P  .02) in a multivariable model accounting for all
variables that were significant predictors of survival in the original
ZEST trial (baseline opioids, HR1.75, 95% CI, 1.00 to 3.06,P .05;
liver or brain metastases, HR 1.93, 95% CI, 1.02 to 3.65, P .04;
Karnofsky performance status 70, HR 2.21, 95% CI, 1.23 to 3.99,
P .008; and alkaline phosphatase 101U/L, HR 2.30, 95% CI,
1.31 to 4.03, P .004).12
The only baseline variable associated with the length of oncolo-
gists’ survival estimates was primary breast cancer (estimates 4.5
months longer than for other primary sites, 95% CI, 1.4 to 7.6; P
.005). Established and readily available prognostic factors such as
performance status, sites of metastases, and symptoms recognized by
the oncologist were not associated with estimated survival.
DISCUSSION
Oncologists’ estimates of survival time for individual patients in this
study were relatively well-calibrated and independently associated
with the patients’ OSTs, even after adjusting for established prognostic
factors. The point estimates of survival time were rarely accurate, but
simple multiples of these estimates accurately estimated worst-case
( one quarter times estimated), typical (half to double estimated)
and best-case (three or more times estimated) scenarios for survival.
The only baseline characteristic associated with the length of oncolo-
gists’ survival estimates was primary breast cancer, suggesting that
other unmeasured characteristics perceived by oncologists contribute
to their survival estimates for individual patients.
Patients in this study were selected on the basis of feeling de-
pressed, anxious, tired, or weak, but their baseline characteristics were
otherwise similar to patients in a typical medical oncology clinic: most
were receiving anticancer treatment, most had a good performance
status, and their median survival was 11 months. The median time
from diagnosis of advanced cancer to study enrollment was 8.5
months, distinguishing these patients from those in our previous
study who had been newly referred to a medical oncologist.9 Despite
this difference, oncologists’ estimates of survival time remained rela-
tively well-calibrated, with approximately 50% of patients living either
less than or longer than their oncologist’s estimate. The tendency of
clinicians to overestimate survival in patients with advanced cancer
and a median survival time less than 12 weeks, seen in previous studies,
was not seen in this study of patients earlier in their disease trajectory
and with a longer median survival.13,28 If anything, there was a trend
toward oncologists underestimating patient’s median survival.
The inherent uncertainty of prognostication is further high-
lighted by the observation that 10% of patients in our study died
within 3 months, despite eligibility criteria including a life expectancy
more than 3 months and Eastern Cooperative Oncology Group per-
formance status of 0 to 2. As expected, only 29% of oncologists’ point
estimates of the median survival of a group of similar patients met an
arbitrary definition of precision. The C-statistic of 0.63 corroborates
the conclusion that oncologists’ estimates of survival time were mod-
erately correlated with their patients’ OSTs. Given the inherent vari-
ability of survival time, it is unrealistic to expect point estimates of
survival time to be any more accurate. However, scenarios for survival
time based on these point estimates were remarkably accurate. The
proportions of patients with an observed survival time bounded by
simple multiples of their estimated survival time (6% one quarter,
Fr
eq
ue
nc
y
Estimated Survival Time (months)
35
25
30
20
0
5
10
15
43 86 109 151412 302418 36
Fig 2. Frequency distribution of oncologists’ survival estimates.
0
Ob
se
rv
ed
 S
ur
vi
va
l T
im
e 
(m
on
th
s)
Estimated Survival Time (months)
36
30
24
18
12
6
6 12 18 24 30 36
Patients who are still alive
Patients who have died
Fig 3. Observed versus estimated survival for each individual. Points on the
45-degree line signify people who lived exactly as long as predicted, points above
the line signify people who lived longer than predicted, and points below the line
signify people who lived shorter than predicted.
543210
Al
iv
e 
(p
ro
po
rti
on
)
Observed-to-Estimated Survival
1.0
0.8
0.6
0.4
0.2
No. at risk 114 44 10 6 3 0
Fig 4. Kaplan-Meier distribution of observed-to-estimated survival time ratios.
Kiely et al
3568 © 2013 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
Downloaded from ascopubs.org by University of Queensland on February 1, 2017 from 130.102.082.083
Copyright © 2017 American Society of Clinical Oncology. All rights reserved.
63% from half to double, and 14% three or more) corresponded
reasonably well with our hypothesized proportions based on previous
studies (5% to 10%, 50%, 5% to 10%).9-11
An estimated worst-case scenario of one quarter of the EST is
probably optimal for patients who would be eligible for conventional
clinical trials, like those in this study. An estimated worst-case scenario
of one sixth of the EST might be more appropriate for patients in
routine practice who would be ineligible for a conventional clinical
trial. In practice, this distinction is more of academic than practical
importance, because when the estimated survival time is 2 years or less,
the difference between multiples of one quarter and one sixth is 2
months or less.
EST was an independently significant predictor of observed sur-
vival in multivariable models after allowing for other prognostic fac-
tors including symptoms, laboratory values, and performance status.
This confirms that the oncologists’ estimates provide additional prog-
nostic information, above and beyond that provided by established
and measureable prognostic factors. Although leukocytosis, lympho-
cytopenia, elevated NLR, and elevated C-reactive protein have been
significant predictors of shorter survival in other studies, they were not
independently significant predictors in this cohort.18-26
The presence and severity of specific symptoms have been indi-
cators of shorter survival in previous studies in advanced cancer.29,30
Dry mouth, anorexia, weight loss, and dysphagia are symptoms of the
cancer anorexia-cachexia syndrome, and there is strong evidence for
their association with a poorer prognosis.18,31,32 Dry mouth was the
only symptom independently associated with shorter survival in our
study, and it was the strongest predictor of OST in the multivariable
Table 2. Factors Associated With Observed Survival Time
Variable No. %
Univariable Models Multivariable Model
HR 95% CI P HR 95% CI P
Estimated survival time,† months 114 100 0.94 0.89 to 0.98 .01 0.92 0.87 to 0.98 .004
Treatment group
Sertraline (v placebo) 56 49 1.21 0.75 to 1.96 .4
Primary site
Prostate 14 12 0.33 0.13 to 0.84 .02 0.23 0.09 to 0.59 .002
Lung 17 15 1.65 0.91 to 2.99 .1
Colorectal 18 16 1.36 0.73 to 2.56 .3
Breast 21 18 0.99 0.49 to 2.02 .9
Past treatment
Steroids at baseline 12 11 2.09 1.06 to 4.11 .03 2.35 1.16 to 4.77 .02
Opioids at baseline 29 25 1.93 1.13 to 3.31 .02
Chemotherapy in the past 86 75 1.21 0.69 to 2.13 .5
Metastases at baseline, liver or brain 38 33 1.79 1.04 to 3.07 .04
Performance status at baseline
Karnofsky 50-70 (v 80-100) 29 25 2.04 1.16 to 3.58 .01 2.30 1.26 to 4.20 .007
ECOG 2 (v 0-1) 24 21 1.56 0.84 to 2.9 .2
Blood tests at baseline
Alkaline phosphatase  101 U/L 54 47 2.02 1.24 to 3.31 .005 2.80 1.64 to 4.78 .0002
Neutrophil lymphocyte ratio  5 32 28 2.09 1.23 to 3.56 .006
Neutrophils  4.75  109/L 57 50 1.63 1.00 to 2.66 .05
Albumin  38 g/L 51 45 1.57 0.96 to 2.58 .07
Hemoglobin  123 g/L 53 46 1.45 0.89 to 2.37 .1
Bilirubin  9 mmol/L 54 47 0.66 0.40 to 1.09 .1
Creatinine  74 mol/L 54 47 0.66 0.40 to 1.09 .1
Lymphocytes  1.5  109/L 54 47 1.16 0.71 to 1.88 .5
C-reactive protein  10 mg/L 50 44 1.20 0.73 to 1.98 .5
Male sex 61 54 1.2 0.73 to 1.95 .5
Body weight at baseline,  76 kg 60 53 1.53 0.93 to 2.51 .1
Age at baseline,  65 years 54 47 0.8 0.49 to 1.3 .4
Time between diagnosis and advanced
disease,  9 months 61 54 2.23 1.33 to 3.73 .002
Symptoms specifically recorded by
oncologist
Dry mouth 21 18 4.36 2.46 to 7.73  .0001 5.07 2.67 to 9.61  .001
Trouble swallowing 9 8 3.49 1.68 to 7.26 .001
Weight loss 33 29 1.93 1.16 to 3.23 .01
Shortness of breath 52 46 1.69 1.04 to 2.75 .03
Appetite problems 45 39 1.64 1.00 to 2.69 .05
Eating problems 20 18 1.12 0.61 to 2.06 .7
Fatigue 102 89 0.92 0.36 to 2.32 .9
Abbreviations: ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio.
Adjusted for univariable predictors that remained significant in a multivariable model selected with backward elimination.
†Fitted as a continuous covariate in the Cox proportional hazards regression model.
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model (HR  5.1; P  .001). The significance of dry mouth as a
predictor of shorter survival time warrants further research.
Breast cancer was the only characteristic associated with the
length of oncologists’ estimates of survival time, consistent with a
previous report that primary site was the criterion used most fre-
quently by eight doctors to estimate survival in 269 patients.33 Loca-
tion of metastases, anorexia, and weakness were also frequently used
in that study, but were not associated with EST in our study. Symp-
toms were recognized and recorded by oncologists, but did not seem
to influence oncologists’ survival estimates in our data set. Perfor-
mance status was not associated with EST in this study, probably
reflecting patient selection inherent in a clinical trial. Other factors that
might influence EST, but were not recorded in this study, include
response to previous treatment, rate of disease progression, comor-
bidities, the predicting oncologist’s experience, and length of relation-
ship with the patient.
The strengths of this study are its prospective design, follow-up,
and inclusion of a broad cross-section of patients with advanced
cancer and a median survival of approximately 1 year. Although the
population is more representative of a typical medical oncology out-
patient practice than studies of hospice patients with a median survival
of a few weeks, all patients were well enough, willing, and able to enroll
in a clinical trial. This limits the direct applicability of our results to
similar populations. Another limitation is the moderate number of
deaths (n  68) and significant number still alive (n  46); more
precise estimates would be produced if the ZEST trial had continued
longer follow-up for survival. The number of participating oncologists
was small (n 21), and all were investigators in a trial of supportive
care. Evaluating survival estimates from a larger number of oncolo-
gists from the wider community would help determine the broader
applicability of our results and conclusions.
Our work suggests that when quantitative information about life
expectancy is sought, oncologists should estimate the median survival
in a group of similar patients. A pertinent clinical trial may provide a
good starting point for this estimate, with adjustments to account for
differences between the individual in question and the study popula-
tion. Rather than presenting a single number estimate of the median to
a patient, we recommend that oncologists use simple multiples of this
estimate to calculate and explain worst-case, typical, and best-case
scenarios for survival. For example, if an oncologist estimates the
median survival in a group of similar patients to be 6 months, then
they can explain that 5% to 10% of similar patients would be expected
to die within 6 weeks (one quarter  6 months), 50% would be
expected to live from 3 to 12 months (half to double 6 months), and
5% to 10% would be expected to live beyond 18 months (3  6
months). The probability of the actual survival times conforming to
these scenarios was remarkably close to that predicted by our previ-
ous work.
In addition to being more accurate than a single point estimate,
providing three scenarios conveys realistic hope that survival might be
considerably longer and a realistic appreciation that it might be con-
siderably shorter. This is supported by our survey of 500 patients with
cancer that showed that significantly more respondents agreed that
explaining three scenarios (v median survival) made sense, was help-
ful, was preferable, conveyed hope, reassured, and was less upsetting.3
Oncologists’ estimates of survival time in this study were
imprecise, but independently associated with OST and sufficiently
well-calibrated to be useful for accurately estimating and explaining
worst-case, typical, and best-case scenarios in patients with advanced
cancer. Providing patients with a point estimate of survival conveys
unwarranted precision and little meaning. We recommend that on-
cologists use simple multiples of their estimated median survival in a
group of similar patients to estimate and explain three scenarios for
survival. Improving the way oncologists estimate and explain survival
time should improve patient understanding and lead to better in-
formed decisions about treatment and plans for the future.
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Appendix
Table A1. Factors Associated With Length of Oncologists’ Survival Estimates
Variable No. %
Between-Group Difference in
Estimated Survival (months) 95% CI P
Treatment group, sertraline (v placebo) 56 49 0.50 2.01 to 3.01 .69
Primary site
Lung 17 15 1.60 5.11 to 1.91 .37
Colorectal 18 16 1.48 4.91 to 1.95 .40
Prostate 14 12 1.83 5.64 to 1.98 .34
Breast 21 18 4.49 1.36 to 7.61 .01
Past treatment
Opioids at baseline 29 25 1.95 4.81 to 0.91 .18
Chemotherapy in the past 86 75 1.32 1.59 to 4.23 .37
Steroids at baseline 12 11 1.30 5.38 to 2.78 .53
Metastases at baseline, liver or brain 38 33 1.13 1.52 to 3.79 .40
Performance status at baseline
Karnofsky 50-70 (v 80-100) 29 25 1.95 4.81 to 0.91 .18
ECOG 2 (v 0-1) 24 21 1.68 4.75 to 1.38 .28
Time between diagnosis and advanced disease
 9 months
61 54 0.53 3.06 to 2.01 .68
Blood tests at baseline
Alkaline phosphatase  101 U/L 54 47 1.87 4.39 to 0.65 .14
C-reactive protein  10 mg/L 50 44 0.90 3.46 to 1.66 .49
Hemoglobin  123 g/L 53 46 1.38 3.88 to 1.13 .28
Albumin  38 g/L 51 45 1.67 4.20 to 0.87 .20
Lymphocytes  1.5  109/L 54 47 2.45 0.02 to 4.93 .05
Bilirubin  9 mmol/L 54 47 1.12 1.39 to 3.62 .38
Creatinine  74 mol/L 54 47 0.06 2.45 to 2.58 .96
Neutrophils  4.75  109/L 57 50 0.81 3.31 to 1.7 .53
NLR  5 32 28 2.08 4.85 to 0.69 .14
Male sex 61 54 1.69 4.19 to 0.81 .18
Body weight at baseline,  76 kg 60 53 1.75 4.24 to 0.74 .17
Age at baseline,  65 years 54 47 1.66 4.16 to 0.83 .19
Symptoms specifically recorded by oncologist
Shortness of breath 52 46 1.44 3.95 to 1.06 .26
Eating problems 20 18 0.98 2.32 to 4.27 .56
Appetite problems 45 39 0.33 2.24 to 2.90 .80
Trouble swallowing 9 8 0.39 5.04 to 4.27 .87
Dry mouth 21 18 1.35 4.58 to 1.88 .41
Weight loss 33 29 0.08 2.87 to 2.71 .95
Fatigue 102 89 0.38 4.47 to 3.71 .86
Abbreviations: ECOG, Eastern Cooperative Oncology Group; NLR, neutrophil–lymphocyte ratio.
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